NZ720868A - A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder - Google Patents
A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorderInfo
- Publication number
- NZ720868A NZ720868A NZ720868A NZ72086814A NZ720868A NZ 720868 A NZ720868 A NZ 720868A NZ 720868 A NZ720868 A NZ 720868A NZ 72086814 A NZ72086814 A NZ 72086814A NZ 720868 A NZ720868 A NZ 720868A
- Authority
- NZ
- New Zealand
- Prior art keywords
- dopamine
- asd
- treatment
- pharmaceutically acceptable
- receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306726 | 2013-12-13 | ||
| PCT/EP2014/077635 WO2015086836A1 (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ720868A true NZ720868A (en) | 2022-04-29 |
Family
ID=49883003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ720868A NZ720868A (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10028948B2 (https=) |
| EP (1) | EP3079688B1 (https=) |
| JP (1) | JP6419826B2 (https=) |
| KR (1) | KR102280530B1 (https=) |
| CN (1) | CN105792824B (https=) |
| AU (1) | AU2014363428B2 (https=) |
| BR (1) | BR112016012552A8 (https=) |
| CA (1) | CA2932791C (https=) |
| CY (1) | CY1119907T1 (https=) |
| DK (1) | DK3079688T3 (https=) |
| ES (1) | ES2657706T3 (https=) |
| HR (1) | HRP20180323T8 (https=) |
| HU (1) | HUE036035T2 (https=) |
| IL (1) | IL245996B (https=) |
| LT (1) | LT3079688T (https=) |
| MA (1) | MA39076A1 (https=) |
| MX (1) | MX372922B (https=) |
| MY (1) | MY172937A (https=) |
| NO (1) | NO3079688T3 (https=) |
| NZ (1) | NZ720868A (https=) |
| PL (1) | PL3079688T3 (https=) |
| PT (1) | PT3079688T (https=) |
| RS (1) | RS56931B1 (https=) |
| RU (2) | RU2019104946A (https=) |
| SA (1) | SA516371298B1 (https=) |
| SI (1) | SI3079688T1 (https=) |
| TN (1) | TN2016000213A1 (https=) |
| UA (1) | UA117271C2 (https=) |
| WO (1) | WO2015086836A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53866B1 (sr) | 2008-07-16 | 2015-08-31 | Richter Gedeon Nyrt. | Farmaceutske formulacije koje sadrže ligande dopaminskih receptora |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| TWI884984B (zh) * | 2019-09-11 | 2025-06-01 | 英商牛津生物力學公眾有限公司 | 診斷染色體標記 |
| KR20220021157A (ko) | 2020-08-13 | 2022-02-22 | 원광대학교산학협력단 | 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2682953B1 (fr) | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
| DE4229880A1 (de) * | 1992-09-04 | 1994-03-31 | Knauf Siegfried | Medikament bzw. Medikamentenzusammensetzung |
| WO2000021951A1 (en) * | 1998-10-08 | 2000-04-20 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| CA2580619C (en) * | 2004-09-20 | 2013-11-12 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
| FR2949465B1 (fr) * | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012157463A1 (en) * | 2011-05-13 | 2012-11-22 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device |
| FR2976179A1 (fr) * | 2011-06-09 | 2012-12-14 | Pf Medicament | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |
-
2014
- 2014-12-12 RU RU2019104946A patent/RU2019104946A/ru unknown
- 2014-12-12 WO PCT/EP2014/077635 patent/WO2015086836A1/en not_active Ceased
- 2014-12-12 PT PT148124654T patent/PT3079688T/pt unknown
- 2014-12-12 AU AU2014363428A patent/AU2014363428B2/en not_active Ceased
- 2014-12-12 PL PL14812465T patent/PL3079688T3/pl unknown
- 2014-12-12 RU RU2016125829A patent/RU2686110C1/ru active
- 2014-12-12 LT LTEP14812465.4T patent/LT3079688T/lt unknown
- 2014-12-12 NZ NZ720868A patent/NZ720868A/en not_active IP Right Cessation
- 2014-12-12 MX MX2016007612A patent/MX372922B/es active IP Right Grant
- 2014-12-12 UA UAA201607311A patent/UA117271C2/uk unknown
- 2014-12-12 US US15/103,470 patent/US10028948B2/en active Active
- 2014-12-12 CA CA2932791A patent/CA2932791C/en active Active
- 2014-12-12 HU HUE14812465A patent/HUE036035T2/hu unknown
- 2014-12-12 BR BR112016012552A patent/BR112016012552A8/pt not_active Application Discontinuation
- 2014-12-12 SI SI201430603T patent/SI3079688T1/en unknown
- 2014-12-12 HR HRP20180323TT patent/HRP20180323T8/hr unknown
- 2014-12-12 RS RS20180196A patent/RS56931B1/sr unknown
- 2014-12-12 DK DK14812465.4T patent/DK3079688T3/da active
- 2014-12-12 EP EP14812465.4A patent/EP3079688B1/en not_active Not-in-force
- 2014-12-12 NO NO14812465A patent/NO3079688T3/no unknown
- 2014-12-12 JP JP2016538587A patent/JP6419826B2/ja not_active Expired - Fee Related
- 2014-12-12 MA MA39076A patent/MA39076A1/fr unknown
- 2014-12-12 KR KR1020167015313A patent/KR102280530B1/ko not_active Expired - Fee Related
- 2014-12-12 MY MYPI2016702136A patent/MY172937A/en unknown
- 2014-12-12 ES ES14812465.4T patent/ES2657706T3/es active Active
- 2014-12-12 CN CN201480066587.4A patent/CN105792824B/zh not_active Expired - Fee Related
- 2014-12-12 TN TN2016000213A patent/TN2016000213A1/en unknown
-
2016
- 2016-06-02 IL IL245996A patent/IL245996B/en active IP Right Grant
- 2016-06-12 SA SA516371298A patent/SA516371298B1/ar unknown
-
2018
- 2018-02-09 CY CY20181100159T patent/CY1119907T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014363428B2 (en) | A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder | |
| US12551474B2 (en) | Use of pridopidine for the treatment of fragile X syndrome | |
| JP2012514011A (ja) | Ｎａｐを用いる併用治療の方法 | |
| US20250235443A1 (en) | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection | |
| WO2016192687A1 (en) | New use of inhibitor of cystine-glutamate transporter | |
| OA17906A (en) | A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder. | |
| SuttonBrown et al. | Clinical and research advances in Huntington's disease | |
| HK1223563B (zh) | 色酮衍生物作为多巴胺d3受体拮抗剂用於治疗自闭症谱系障碍的用途 | |
| JP4462382B1 (ja) | Ｄ−アスパラギン酸オキシダーゼおよびｄ−アミノ酸オキシダーゼに対する新規阻害剤 | |
| RU2812786C2 (ru) | Применение ролуперидона для лечения негативных симптомов и заболеваний, повышения нейропластичности и содействия нейрозащите | |
| Fonteneau et al. | Tilted striatofugal balance and beneficial effects of facilitating mGlu4 receptor activity in the Fmr1-/-mouse model of Fragile X Syndrome | |
| Konttinen et al. | Microglial amyloid beta clearance is driven by PIEZO1 channels | |
| Class et al. | Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research | |
| EP4395754A1 (en) | Methods for treating autism spectrum disorders | |
| CN121604971A (zh) | 用于治疗与焦虑症相关的认知障碍的hip/pap蛋白或其衍生物 | |
| Jensen | Serotonin: from mouse models to human disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |